文献速递白血病

索拉非尼联合5-阿扎胞苷治疗老年初治FLT3-ITD突变急性髓系白血病

Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.
PubMed 文献 · Am J Hematol · 2018-08-31

在27例中位年龄74岁、不适合标准化疗的初治FLT3突变急性髓系白血病患者中,评估索拉非尼联合5-阿扎胞苷的疗效与耐受性;总缓解率78%,中位总生存8.3个月,方案耐受良好且无早期死亡。

要点

  • 初治FLT3突变AML老年患者中,索拉非尼联合5-阿扎胞苷总缓解率为78%。
  • 全组中位总生存8.3个月,19例缓解者为9.2个月。
  • 方案在老年初治FLT3突变AML中耐受良好,无早期死亡。

核心结论

  • 索拉非尼联合5-阿扎胞苷在因高龄或体能不适合标准化疗的初治FLT3突变AML患者中显示出疗效且耐受良好,无早期死亡。

研究设计与样本

  • 分析了两项独立方案(NCT02196857和NCT01254890)中接受一线5-阿扎胞苷联合索拉非尼治疗的初治FLT3突变AML患者。
  • 共纳入27例初治FLT3突变AML患者,中位年龄74岁(范围61-86岁)。

主要发现

  • 总缓解率为78%,其中完全缓解(CR)7例(26%),CRi/CRp 12例(44%),部分缓解(PR)2例(7%)。
  • 患者接受中位3个治疗周期(范围1-35)。
  • CR/CRp/CRi的中位持续时间为14.5个月(范围1.1-28.7个月)。
  • 3例(11%)缓解患者(1例CR,2例CRi)接受了异基因干细胞移植。
  • 存活患者的中位随访时间为4.1个月(范围3.0-17.3个月);全组中位总生存为8.3个月,19例缓解者为9.2个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Based on our previous study of the combination of sorafenib with 5-azacytidine (AZA) in relapsed/refractory patients with FLT3 mutated acute myeloid leukemia (AML), we hypothesized that the combination would be efficacious and well tolerated in untreated patients with FLT3 mutated AML who are unsuitable for standard chemotherapy due to advanced age or lack of fitness. Newly diagnosed patients with untreated FLT3 mutated AML who underwent frontline therapy on 2 separate protocols of AZA plus sorafenib were analyzed. The clinical trials were registered at clinicaltrials.gov (NCT02196857 and NCT01254890). Overall, 27 patients with untreated FLT3 mutated AML (median age of 74 years, range, 61-86) were enrolled. The overall response rate was 78% (7 [26%] CR, 12 [44%] CRi/CRp, and 2 [7%] PR). Patients received a median of 3 treatment cycles (1-35). The median duration of CR/CRp/CRi is 14.5 months (1.1-28.7 months). Three (11%) responding patients (1 CR, 2 CRi) proceeded to allogeneic stem cell transplant. The median follow-up for surviving patients was 4.1 months (3.0-17.3 months). The median overall survival for the entire group was 8.3 months, and 9.2 months in the 19 responders. The regimen was well tolerated in elderly patients with untreated FLT3 mutated AML with no early deaths.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Ohanian M, Garcia-Manero G, Levis M, et al. Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol. 2018. PMID: 30028037. doi:10.1002/ajh.25198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。